Navigation Links
Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Obagi Medical Products, Inc.
Date:4/25/2013

LAVAL, Quebec, April 25, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced the expiration of the tender offer (the "Offer") by a subsidiary of Valeant Pharmaceuticals International ("VPI") to purchase all of the outstanding shares of Obagi Medical Products, Inc. (NASDAQ: OMPI) ("Obagi") for a price of $24 per share in cash, without interest (less any applicable withholding taxes). 

The Offer expired at midnight, New York City time, on April 25, 2013.  American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, has advised that, as of the expiration of the Offer, a total of 14,708,133 shares had been tendered into and not withdrawn from the Offer, representing approximately 84.12% of Obagi's outstanding shares.  Additionally, the depositary has advised that an additional 938,189 shares had been tendered by notice of guaranteed delivery. The condition to the Offer that at least a majority of the outstanding shares of Obagi common stock (on a fully diluted basis) be validly tendered and not properly withdrawn prior to the expiration of the Offer has been satisfied.  Accordingly, all shares that were validly tendered and not properly withdrawn were accepted for payment and Valeant will promptly pay for all such tendered shares in accordance with the terms of the Offer.  Valeant intends to exercise its top-up option to acquire additional Obagi shares.  As a result of the tenders and the top-up option exercise, Valeant will own more than 90% of the outstanding Obagi shares than 90% of the outstanding Obagi shares (on a fully diluted basis) and expects to complete today the acquisition of Obagi through a "short form" merger
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. American Skin Association Announces New Member Of The Board J. Michael Pearson And New Education Council Member Ryan Weldon Of Valeant Pharmaceuticals International, Inc.
2. Valeant Pharmaceuticals International, Inc. Announces Receipt of Approval From the Antimonopoly Committee of Ukraine for its Previously Announced Acquisition of Obagi Medical Products, Inc.
3. Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc.
4. Valeant Pharmaceuticals To Announce 2013 First Quarter Results On May 2, 2013
5. Valeant Pharmaceuticals Provides Update to Recent Event
6. Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash
7. Valeant Pharmaceuticals Announces Private Exchange Offer
8. Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash
9. Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results
10. Valeant Completes Acquisition Of Natur Produkt In Russia
11. Valeant Pharmaceuticals To Announce 2012 Fourth Quarter Results On February 28, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Lockton Dunning Benefits, the ... the addition of Vice President Kim Foerster ... Pharmacy Consulting team, Excelsior Solutions. ... to the position.  Most recently, she worked as ... Specialty Pharmacy, where she has held various managerial ...
(Date:12/24/2014)... , Dec. 23, 2014 Tianyin ... company that specializes in patented biopharmaceutical, modernized traditional ... ingredients (API) today announced that the Company achieved ... Good Manufacturing Practice (GMP) certificate of TPI,s Qionglai ... Administration,s (CFDA). The public notice period is a ...
(Date:12/24/2014)... , Dec. 23, 2014  Endo Pharmaceuticals Inc., ... ENDP ) (TSX: ENL), and BioDelivery Sciences International, Inc. ... have submitted a New Drug Application (NDA) for Buprenorphine ... Administration (FDA).  Buprenorphine HCl Buccal Film is under development ... daily, around-the-clock, long-term opioid treatment and for which alternative ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... Massachusetts General Hospital (MGH) Cancer Center has purchased four ... Elekta Infinity and one Elekta Synergy® S. The ... will enable the facility to offer patients a complete cancer ... Infinity systems position MGH to take advantage of ...
... Foundation of America (AAFA) announced today the 2009 Fall Allergy ... 100 most challenging cities for people with fall allergies. ... Wichita, KS (2); Louisville, KY (3); Oklahoma City, OK (4); ... recent AAFA survey, fall is also one of the most ...
Cached Medicine Technology:Massachusetts General Hospital Selects Elekta As New Vendor for Complete Cancer Treatment Solution 2New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 2New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 3New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 4New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 5New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 6
(Date:12/25/2014)... (PRWEB) December 26, 2014 The report ... 2023” focuses on the current treatment landscape, unmet needs, ... market. TS-1 is an anti-cancer drug which is typically ... and is also used for treating gastric cancer and ... otastat potassium. The drug was first approved in 1999 ...
(Date:12/25/2014)... “Every three months the trends for evening dresses ... will be one of the hottest styles in the next ... the company releases 26 A-line sweetheart evening dresses, and announces ... , “We are trying our best to help a lady ... Along with affordable prices, we provide discounted delivery costs to ...
(Date:12/25/2014)... Dylan Queen, a famous online company supplying women’s special ... prom dresses, most of which are priced under $200. ... the promotion is valid until Jan. 22, 2015; the ... market. , The prom dresses in this new collection ... strapless, empire strapless chiffon, one shoulder, floor-length, V-neck beading, ...
(Date:12/25/2014)... BellasDress has launched its Christmas Sale, offering ... chosen their best-selling lace wedding dresses, vintage bridesmaid dresses ... , Now, BellasDress.com features popular women’s dresses, and ... prices. The business hopes everyone can have a memorable ... “All our elegant products are made with exquisite materials; ...
(Date:12/25/2014)... 25, 2014 Helen Harris’ RP (Retinitis ... Hills, California after an 8 year battle with breast ... Eve evening in her home in Woodland Hills California ... cancer. , As the founder and ... she pioneered and championed many of today's greatest breakthroughs ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... is leading a project to provide technical assistance to ... national HIV strategy and programme of support. The ... the Delegation of the European Commission to Libya. ... LSTM in partnership with Libyan institutions and Harvard University,s ...
... , WALTHAM, Mass., Aug. 4 ... research and advisory firms for pharmaceutical and healthcare issues, ... emerging protease inhibitors, surveyed physicians indicate that they will ... 50 percent of their hepatitis C virus genotype 1-infected ...
... , , COLD SPRING ... the world,s first hand-held, non-contact vein illumination device, announced today that ... to commence European sales of AccuVein,s AV300. , , ... an important step in bringing this beneficial device to healthcare practitioners ...
... High cholesterol, hypertension, diabetes and smoking raise Alzheimer,s risk ... things that are bad for your heart in the ... blood pressure, smoking, diabetes -- are bad for your ... cholesterol levels in midlife were associated with an increased ...
... , NEW YORK, Aug. 4 ... ) announced today that the Company and Alfa Wassermann S.p.A. ... license agreement for Sulonex (sulodexide). Under the terms of the ... US$2,750,000 has already been received by Keryx and $750,000 is ...
... , , , SADDLE ... http://www.kessler-rehab.com ) is the only hospital ... in the country to offer amputees the new PROPRIO FOOT(R), ... users. This advanced bionic technology, developed by Ossur, a global ...
Cached Medicine News:Health News:LSTM leads project to develop HIV/AIDS strategy for Libya 2Health News:Surveyed Physicians Will Treat Over 50 Percent of Hepatitis C Genotype 1-Infected Patients With the Protease Inhibitor Telaprevir 2Health News:Surveyed Physicians Will Treat Over 50 Percent of Hepatitis C Genotype 1-Infected Patients With the Protease Inhibitor Telaprevir 3Health News:AccuVein Vein Illuminator Receives European CE Mark 2Health News:Midlife Heart Risk Factors Linked to Later Dementia 2Health News:Midlife Heart Risk Factors Linked to Later Dementia 3Health News:Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann 2Health News:Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann 3Health News:Kessler Institute for Rehabilitation Only Hospital in New Jersey to Offer New Bionic Foot to Amputees 2Health News:Kessler Institute for Rehabilitation Only Hospital in New Jersey to Offer New Bionic Foot to Amputees 3
... enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative ... serum. The presence of ANA can be ... other laboratory tests to aid in the ... lupus erythematosus, Sjgren's syndrome, scleroderma, and mixed ...
The MESACUP ANA Test Kit is a semi-quantitative enzyme-linked immunosorbent assay,(ELISA) for the detection of specific anti-nuclear antibodies in human serum as an aid in,the determination of autoim...
... Immuno Concepts manufactures slides that are compatible ... to decrease the number of pipetting steps ... sample dilutions on the slides. Ask Immuno ... and these slides. These slide formats are ...
... HEp-2000 ANA uses a patented HEp-2 cell ... increase the sensitivity to SS-A/Ro autoantibodies, without ... independent studies have been published worldwide on ... sensitivity to SS-A/Ro autoantibodies when used in ...
Medicine Products: